|
1
|
Raggatt LJ and Partridge NC: Cellular and
molecular mechanisms of bone remodeling. J Biol Chem.
285:25103–25108. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zaidi M, Blair HC, Moonga BS, Abe E and
Huang CL: Osteoclastogenesis, bone resorption, and osteoclast-based
therapeutics. J Bone Miner Res. 18:599–609. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chambers TJ and Fuller K: How are
osteoclasts induced to resorb bone? Ann N Y Acad Sci. 1240:1–6.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cooper C and Melton LJ III: Epidemiology
of osteoporosis. Trends Endocrinol Metab. 3:224–229. 1995.
View Article : Google Scholar
|
|
5
|
Weitzmann MN and Pacifici R: Estrogen
deficiency and bone loss: An inflammatory tale. J Clin Invest.
116:1186–1194. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fleisch H: Bisphosphonates: Mechanism of
action. Endocr Rev. 19:80–100. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mottaghi P: Intravenous bisphosphonates
for postmenopausal osteoporosis. J Res Med Sci. 15:175–184.
2010.PubMed/NCBI
|
|
8
|
Caro JJ, Ishak KJ, Huybrechts KF, Raggio G
and Naujoks C: The impact of compliance with osteoporosis therapy
on fracture rates in actual practice. Osteoporos Int. 15:1003–1008.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feng Z, Zeng S, Wang Y, Zheng Z and Chen
Z: Bishosphonates for the prevention and treatment of osteoporosis
in patients with rheumatic diseases: A systematic review and
meta-analysis. PLoS One. 8:e808902013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Newcomb PA, Trentham-Dietz A and Hampton
JM: Bisphosphonates for osteoporosis treatment are associated with
reduced breast cancer risk. Br J Cancer. 102:799–802. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oh YH, Yoon C and Park SM: Bisphosphonate
use and gastrointestinal tract cancer risk: Meta-analysis of
observational studies. World J Gastroentero. 18:5779–5788. 2012.
View Article : Google Scholar
|
|
12
|
Faiman B, Pillai AL and Benghiac AG:
Bisphosphonate-related osteonecrosis of the Jaw: Historical,
ethical, and legal issues associated with prescribing. J Adv Pract
Oncol. 4:25–35. 2013.PubMed/NCBI
|
|
13
|
Cardwell CR, Abnet CC, Veal P, Hughes CM,
Cantwell MM and Murray LJ: Exposure to oral bisphosphonates and
risk of cancer. Int J Cancer. 131:E717–E725. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamaguchi M and Gao-Balch YH: Role of
dietary soybean genistein in osteoporosis prevention. Int J Food
Sci Nutr Diet. 2:27–34. 2013. View Article : Google Scholar
|
|
15
|
Yamaguchi M: Nutritional factors and bone
homeostasis: Synergistic effect with zinc and genistein in
osteogenesis. Mol Cell Biochem. 366:201–221. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamaguchi M and Gao YH: Inhibitory effect
of genistein on bone resorption in tissue culture. Biochem
Pharmacol. 55:71–76. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gao YH and Yamaguchi M: Inhibitory effect
of genistein on osteoclast-like cell formation in mouse marrow
cultures. Biochem Pharmacol. 58:767–772. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao YH and Yamaguchi M: Anabolic effect of
daizein on cortical bone in tissue culture: Comparison with
genistein effect. Mol Cell Biochem. 194:93–98. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yamaguchi M and Sugimoto E: Stimulatory
effect of genistein and daizein on protein synthesis in
osteoblastic MC3T3-E1 cells: Activation of aminoacyl-tRNA
synthetase. Mol Cell Biochem. 214:97–102. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamaguchi M and Weitzmann MN: The estrogen
17beta-estradiol and phytoestrogen genistein mediate differential
effects on osteoblastic NF-kappaB activity. Int J Mol Med.
23:297–301. 2009.PubMed/NCBI
|
|
21
|
Yamaguchi M and Weitzmann MN: The intact
strontium ranelate complex stimulates osteoblastogenesis and
suppresses osteoclastogenesis by antagonizing NF-κB activation. Mol
Cell Biochem. 359:399–407. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamaguchi M and Weitzmann MN: Vitamin K2
stimulates osteoblastogenesis and suppresses osteoclastogenesis by
suppressing NF-κB activation. Int J Mol Med. 27:3–14.
2011.PubMed/NCBI
|
|
23
|
Yamaguchi M and Daimon Y: Overexpression
of regucalcin suppresses cell proliferation in cloned rat hepatoma
H4-II-E cells: Involvement of intracellular signaling factors and
cell cycle-related genes. J Cell Biochem. 95:1169–1177. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Izumi T and Yamaguchi M: Overexpression of
regucalcin suppresses cell death in cloned rat hepatoma H4-II-E
cells induced by tumor necrosis factor-alpha or thapsigargin. J
Cell Biochem. 92:296–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
García Palacios V, Robinson LJ, Borysenko
CW, Lehmann T, Kalla SE and Blair HC: Negative regulation of
RANKL-induced osteoclastic differentiation in RAW264.7 cells by
estrogen and phytoestrogens. J Biol Chem. 280:13720–13727. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee SH, Kim JK and Jang HD: Genistein
inhibits osteoclastic differentiation of RAW267.4 cells via
regulation of ROS production and scavenging. Int J Mol Sci.
15:10605–10621. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gao YH and Yamaguchi M: Suppressive effect
of genistein on rat bone osteoclasts: Involvement of protein kinase
inhibition and protein tyrosine phosphatase activation. Int J Mol
Med. 5:261–267. 2000.PubMed/NCBI
|
|
28
|
Sutherland KA, Rogers HL, Tosh D and
Rogers MJ: RANKL increases the level of Mcl-1 in osteoclasts and
reduces bisphosphonate-induced osteoclast apoptosis in vitro.
Arthritis Res Ther. 11:R582009. View
Article : Google Scholar : PubMed/NCBI
|
